The metabolic syndrome is a cluster of cardiovascular risk factors, including insulin resistance, obesity, atherogenic dyslipidemia, and hypertension. These conditions are interconnected and share common underlying mechanisms. The concept is important for identifying patients at high risk of cardiovascular disease and type 2 diabetes. A comprehensive definition would help in research and treatment approaches. Several definitions of the metabolic syndrome have been proposed. The World Health Organization (WHO) definition requires insulin resistance, obesity, dyslipidemia, and hypertension. The European Group for the Study of Insulin Resistance (EGIR) definition also requires insulin resistance but uses simpler criteria. The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) definition is widely used, requiring three or more of five criteria, including waist circumference, blood pressure, triglycerides, HDL cholesterol, and fasting blood sugar. The International Diabetes Foundation (IDF) definition focuses on obesity but not necessarily insulin resistance. The concept of metabolic syndrome has practical uses in clinical practice for identifying patients at higher risk of T2D and CVD. However, it does not account for all risk factors, such as family history of diabetes, age, gender, smoking, LDL, and total cholesterol levels. Therefore, it may be less effective than other risk assessment tools. The metabolic syndrome is characterized by insulin resistance, visceral obesity, atherogenic dyslipidemia, and endothelial dysfunction. These features are interrelated and share common pathophysiological mechanisms. A comprehensive definition should include these four features. Insulin resistance is a key feature of the metabolic syndrome, leading to impaired glucose uptake and increased circulating glucose levels. It is associated with a variety of vascular and metabolic abnormalities. Visceral obesity contributes to insulin resistance and atherogenic dyslipidemia through the release of adipokines and free fatty acids. Atherogenic dyslipidemia is characterized by high triglycerides, low HDL cholesterol, and increased small dense LDL. Endothelial dysfunction is a common feature of the metabolic syndrome, contributing to atherosclerosis and CVD. The metabolic syndrome is a complex condition with multiple interrelated features. A comprehensive definition would help in understanding its pathophysiology and developing effective treatment approaches. The NCEP ATP III definition is the most widely used and clinically applicable. Despite ongoing controversy, the concept of metabolic syndrome is important for identifying patients at high risk of CVD and T2D.The metabolic syndrome is a cluster of cardiovascular risk factors, including insulin resistance, obesity, atherogenic dyslipidemia, and hypertension. These conditions are interconnected and share common underlying mechanisms. The concept is important for identifying patients at high risk of cardiovascular disease and type 2 diabetes. A comprehensive definition would help in research and treatment approaches. Several definitions of the metabolic syndrome have been proposed. The World Health Organization (WHO) definition requires insulin resistance, obesity, dyslipidemia, and hypertension. The European Group for the Study of Insulin Resistance (EGIR) definition also requires insulin resistance but uses simpler criteria. The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) definition is widely used, requiring three or more of five criteria, including waist circumference, blood pressure, triglycerides, HDL cholesterol, and fasting blood sugar. The International Diabetes Foundation (IDF) definition focuses on obesity but not necessarily insulin resistance. The concept of metabolic syndrome has practical uses in clinical practice for identifying patients at higher risk of T2D and CVD. However, it does not account for all risk factors, such as family history of diabetes, age, gender, smoking, LDL, and total cholesterol levels. Therefore, it may be less effective than other risk assessment tools. The metabolic syndrome is characterized by insulin resistance, visceral obesity, atherogenic dyslipidemia, and endothelial dysfunction. These features are interrelated and share common pathophysiological mechanisms. A comprehensive definition should include these four features. Insulin resistance is a key feature of the metabolic syndrome, leading to impaired glucose uptake and increased circulating glucose levels. It is associated with a variety of vascular and metabolic abnormalities. Visceral obesity contributes to insulin resistance and atherogenic dyslipidemia through the release of adipokines and free fatty acids. Atherogenic dyslipidemia is characterized by high triglycerides, low HDL cholesterol, and increased small dense LDL. Endothelial dysfunction is a common feature of the metabolic syndrome, contributing to atherosclerosis and CVD. The metabolic syndrome is a complex condition with multiple interrelated features. A comprehensive definition would help in understanding its pathophysiology and developing effective treatment approaches. The NCEP ATP III definition is the most widely used and clinically applicable. Despite ongoing controversy, the concept of metabolic syndrome is important for identifying patients at high risk of CVD and T2D.